The strategy of pharmaceutical patent protection: the case of atazanavir

Authors

  • Carla Cristina de Freitas da Silveira Universidade Estadual do Rio de Janeiro, Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil.
  • Marilena Cordeiro Dias Villela Corrêa Universidade Estadual do Rio de Janeiro, Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil.
  • Wanise Borges Gouvea Barroso Fundação Oswaldo Cruz, Farmanguinhos. Rio de Janeiro, RJ, Brasil.

DOI:

https://doi.org/10.29397/reciis.v10i1.1047

Keywords:

Patent, Atazanavir, HIV/Aids, Public health, Intellectual property.

Abstract

The high costs of antiretroviral drugs (ARVs) justifies studies on pharmaceutical patenting strategies vis-à-vis the Brazilian public policy of universal access to ARVs. The analysis of the evolution of technology trends through patent study also provides an overview of those involved in the development of a technology. To trace the patenting profile of atazanavir antiretroviral in Brazil and in the world, a study was conducted using Thomson Reuters Integrity database and such study identified the development, production and marketing of this product. 49 patent documents were identified, having been started the protection of this technology in 1996 with Novartis and its licensee Bristol, which claimed protection for the molecule. It remains until 2013, with protection of incremental inventions originating in China. The study has allowed to discuss the importance of the patent system to promoting innovation, and to highlight different types of protection for a product and related technologies.

Author Biographies

Marilena Cordeiro Dias Villela Corrêa, Universidade Estadual do Rio de Janeiro, Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil.

Wanise Borges Gouvea Barroso, Fundação Oswaldo Cruz, Farmanguinhos. Rio de Janeiro, RJ, Brasil.

Published

2016-03-31

How to Cite

Silveira, C. C. de F. da, Corrêa, M. C. D. V., & Barroso, W. B. G. (2016). The strategy of pharmaceutical patent protection: the case of atazanavir. Revista Eletrônica De Comunicação, Informação & Inovação Em Saúde, 10(1). https://doi.org/10.29397/reciis.v10i1.1047

Issue

Section

Original articles